Equity
€885,230 ▲ 26.4%
VERIPHARM has made a profit without a break since 2015.
VERIPHARM
Lifetime
20 annual accounts with figures on one time axis, 25 filings since 2001peak €437,364 (2018)
€170,272▲ 4.8%
lowest -€40,251 (2014)
€184,855▲ 411%
peak €1.2m (2023)
€885,230▲ 26.4%
€664,382▼ 48.6%
peak 2.3 FTE (2020)
-not published
Board3 names since 2019
1 directorVerelst Louis
Documentsfilings and deeds
02-07-202629 days before the deadline
2025abbreviated format
Result from €36,189 to €184,855Reappointments: Verté Rita (managing director) and Verelst Lo… 01-08Equity from €700,375 to €885,230Debts from €1.3m to €664,382Cash from €109,285 to €75,443
Key points
from the 2025 annual accountsResult
€184,855 ▲ 411%
The result rose in 2025: mostly from a one-off income of €164,087.
Turnover
≈ €260,000 estimated
The accounts state no turnover.
Liquidity
5.00 was 1.07 in 2024
Short-term debts fell from €639,952 to €68,058.
Filings
25 annual accounts since 2001
The last five annual accounts were filed 29 to 33 days before the end of the period.
Position in the sector
€184,855
Higher net result than 84% of companies in office administrative support. Sector median €20,941 · 2,831 companies.
Checked score
95
Excellent
Financially stronger than 58% of micro companies in office administrative support (NACE 82)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 12,672 companies (NACE 82, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%lowest value
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: 0.1%▲ +0.1 percentage points vs 06-2026highest value
08-2026: < 0.1%▼ -0.1 percentage points vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Size: total assets €1.5m
Figures for financial year 2025 (filed on 02-07-2026)
Sector: Office administrative, office support and other business support activities (NACE 82)
Equity €885,230 (57.1% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 82, micro). It does better than 57% of them on solvency, 50% on liquidity, 56% on profitability and 70% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 20,137 companies had the same profile as VERIPHARM has now. Each dot stands for 51 companies, two years later.
95.1%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
That fits the bankruptcy probability of VERIPHARM itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,137 companies, not a prediction for VERIPHARM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €80,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 5.0 (1.07 in 2024), above the usual 1.5. Short-term debt is 4.4% and cash 4.9% of total assets. 42.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
29 days early
2024
30 days early
2023
30 days early
2022
30 days early
2021
33 days early
2020
32 days early
2019
30 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 31 days before the deadline. In the sector (NACE 82), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 1 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0475905160
Reappointments: Verté Rita (managing director) and Verelst Louis (director)
General meeting of 25-06-2025 · Gazette deed
Amendment of the articles
Gazette deed
1 director resigning, 2 reappointments
Resignation: Francis Deprez · Reappointments: Verté Rita (managing director) and Verelst Louis · Director discharge: Francis Deprez · General meeting of 01-06-2019 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| VERIPHARM Mol | €1.5m | €170,272 | 57.1% | - |
| IPRO Mechelen | €1.5m | €153,366 | 58.2% | - |
| DIVIST Brasschaat | €1.5m | €141,740 | 71.6% | - |
| MAPIVAN Wingene | €1.5m | €174,102 | 57.2% | - |
| VAN DER SYPT CONSULTING Lochristi | €1.7m | €166,719 | 96.9% | - |
| WILMOT Nazareth-De Pinte | €1.4m | €136,874 | 51.1% | - |
| LuDa Mara Schilde | €1.2m | €158,328 | 16.3% | - |
These companies have the same main activity as VERIPHARM: other business support services (NACE 82990). They are comparable in size and age: total assets between €1.2m and €1.7m, founded between 1996 and 2003.
Official details
Source: KBO- Status
- Active since 19-10-2001Normal situation
- Activity
- Other business support servicesNACE 82990and 2 others
- Establishment unit
- 2.095.379.9442400 Mol, since 28-11-2001
- Financial year end
- 31 December
- Peppol
- Reachable since 27-01-2026
Annual accounts 2025
- €1.5m▼ 22.3%
- Filing
- Filed on 02-07-2026, 29 days before the end of the filing period
Insights on VERIPHARM
VERIPHARM files the abbreviated format. That format states no turnover. The gross margin fell from €256,172 in 2006 to €170,272 in 2025.
The balance sheet grew most from 2013 to 2015 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about VERIPHARM
- What is the company number of VERIPHARM?
- The company number of VERIPHARM is 0475.905.160. The VAT number is the same number with BE in front: BE 0475.905.160.
- Where is VERIPHARM based?
- The registered office is at St.-Jozefslaan 55, 2400 Mol.Company details
- What does VERIPHARM do?
- According to the KBO register, the main activity is other business support services (NACE 82990).
- What is the legal form of VERIPHARM?
- VERIPHARM is a public limited company (NV).
- When was VERIPHARM founded?
- VERIPHARM was founded on 19-10-2001.
- Is VERIPHARM still active?
- Yes, VERIPHARM is an active enterprise in the KBO register.
- How many employees does VERIPHARM have?
- VERIPHARM had an average of 2.3 full-time equivalents in financial year 2020, according to the filed annual accounts.Financials
- What is the turnover of VERIPHARM?
- The turnover in financial year 2025 is ≈ €260,000. This figure is estimated from the gross margin of €170,272 and 31 comparable companies (NACE 82990). It probably lies between €200,000 and €360,000.
- Is VERIPHARM profitable?
- In financial year 2025, VERIPHARM made a profit of €184,855.
- Where can I find the annual accounts of VERIPHARM?
- VERIPHARM filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of VERIPHARM due?
- VERIPHARM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.